1. INTRODUCTION:

The main aim in drug production is making medicine that’s always safe, works well, and meets top standards. Of all the steps needed for this, checking cleanliness stands out as especially vital. This check proves machines, systems, and surfaces get properly cleaned, stopping leftover stuff like prior meds, soap, or germs from affecting future batches.

Since today's plants often run different drugs on the same gear, poor cleaning might lead to mix-ups, fines from regulators, or worse harm to patients¹. Cleaning checks fit into the everyday mindset of sticking to solid production rules. Back in the 70s or early 80s, it mostly meant just looking at gear to see if it seemed clean; yet today, it's turned into something more methodical and recorded. Groups like the FDA from the U.S., along with EMA, WHO, plus PIC/S all agree now that real proof means lab results alongside clear pass-or-fail limits. Even though they all want the same outcome showing machines are truly clean they each demand backup through repeatable tests, careful hazard reviews, also logical science behind decisions. In the past, test methods relied on rough estimates like 10 parts per million or one-thousandth of a treatment dose. These gave numbers but no real safety backing. As strong drugs, biological agents, and chemo compounds became more common, old math didn't hold up. By the late 2000s, officials started using health focused exposure levels instead called permitted daily exposures (PDE) to set safer limits. A PDE comes from drug and toxicity info, adjusted with safety margins so patients stay safe. That shift changed how we see cleaning checks now it’s less about ticking boxes, instead more like smart risk handling^2,3. As testing got sharper, tools changed. Back then, many labs used UV readings or basic colour tests to spot leftovers now they run HPLC, LC–MS, or TOC checks instead. Swabbing and rinsing evolved too; old wipe trials gave way to proven methods with reliable pickup rates. Together, these shifts showed that solid cleaning proof isn't just about smart setup or correct measurements it's tied closely to how risks are weighed⁴. The Main Goals of Cleaning Validation are Basically this. Stop germs spreading while keeping patients safe. Ensure your product stays reliable by removing leftover stuff that might lead to breakdowns, inconsistency, or failed tests. Show you meet rules by using clear methods that are proven, repeatable, backed with solid proof. Every goal tie to a core part of GMP one keeps patients safe, another ensures steps stay steady, while the third makes proof clear to see. Nowadays, checking if things are clean uses a step-by-step approach much like how we check production steps: plan it, test it, then keep an eye on it. At the planning phase, teams look at risks to pick the hardest-to-clean items, spots, and cleaners. When testing, lab checks confirm methods actually remove enough residue, staying under set limits based on safe exposure levels (PDE). Over time, ongoing checks track daily results so everything stays consistent⁵. Lately, things have changed a bit. New digital setups track validations using e-docs that follow ALCOA rules this boosts accuracy and makes audits smoother. Machines run checks nonstop thanks to live sensors watching rinses via TOC or conductivity, hinting at future always on cleaning proof. Meanwhile, smart software sorts risks so companies can focus tight controls where they matter most. In short, cleaning checks have shifted from just meeting rules to showing real control through science. This keeps patients safe, ensures meds work right, also maintains trust in regulations. By mixing toxicity insights, lab testing, along with smart risk strategies, these validations became key in today’s drug quality setups. Later parts reveal how inspectors want every maker to back their cleanup methods with solid proof, clear records across all stages, plus steady upgrades under global standard practices^6,7.

2. Regulatory Expectations and Guidelines:

Cleaning checks follow GMP rules set by key health agencies worldwide. Even though local laws use different terms, most agree on three ideas: equipment should visibly be cleaned prior to operation, leftover traces need staying under safe limits backed by research, companies have to keep records proving ongoing oversight⁸. The regulatory expectations and guidelines are shown in Figure 1.

Figure 1: Regulatory Expectations and Guidelines

2.1 United States – FDA:

In the U.S., you won't find clear rules about cleaning validation in federal regulations (21 CFR Part 211); they just say equipment must be cleaned, serviced, or disinfected now and then to avoid breakdowns or dirt. Instead, real guidance shows up in FDA inspection notes from 1993 on cleaning checks, along with a 2011 paper explaining how industry should handle process approval. Those papers describe what’s expected like realistic limits for leftovers, reliable wipe-down techniques, tested lab checks, plus solid record keeping. Lately, FDA reviewers focus more on ongoing care: cleaning isn’t something done once when starting up; it's part of constant oversight that moves alongside each phase of process proofing⁹.

2.2 European Union – EMA / European Commission:

The European Commission's EudraLex Volume 4 Annex 15: Qualification and Validation (2015) made it official cleaning checks should rely on health-based exposure limits. Firms now need to apply Permitted Daily Exposure (PDE) or Acceptable Daily Exposure (ADE), based on toxicity reviews, when setting limits for leftover residues. Instead of old rules like 10 ppm or one-thousandth of a dose, this new method uses safer benchmarks drawn from actual health risks. According to Annex 15, clean looks help yet don't count alone; testing procedures plus swab analysis must prove reliable through verified recovery rates. On inspections, EU auditors demand clear reasons behind each pass-fail level, approval from a poison expert on PDE numbers, alongside direct ties linking hazard review to test techniques used^10,11.

2.3 World Health Organization:

The WHO added hygiene rules to its Technical Report Series No. 937 (Annex 3: Validation), along with No. 986 (Annex 2: Good Manufacturing Practices). Its advice lines up with EMA and PIC/S thinking so countries just starting out usually build their own systems on it. They stress solid proof, clear records that show results can be repeated, while checking if both hand cleaning and machine methods actually work. Since many health watchdogs across Africa, Asia, or Latin America rely on WHO GMP basics, these sections end up shaping standards worldwide¹².

2.4 PIC/S – International Harmonization:

The Pharmaceutical Inspection Co-operation Scheme updated its Good Manufacturing Practice Guide Annex 15 (2021) to match the EU’s version, helping keep inspections alike everywhere. Now, under PIC/S rules, firms must figure out HBEL/PDE levels, assess risks, while managing cleaning steps through their full life cycle. Since inspectors from over 50 nations are part of this group, terms like "max allowed residue," "control approach," or "ongoing checks" mean nearly the same thing no matter where you go. In places beyond Europe, using the PIC/S handbook right away lines up national rules with those used in the EU¹³.

2.5 ICH Quality Guidelines:

Though the International Council for Harmonisation doesn’t give direct rules on cleaning, its quality guidelines like Q8, which covers drug development, Q9 that deals with handling risks, plus Q10 about maintaining consistent product standards form a base for how to manage cleaning based on potential problems. These papers place cleaning steps inside the full picture of making drugs, from early design through ongoing upgrades. In particular, ICH Q9 supports using methods like FMEA or scoring systems to decide what needs cleaning; meanwhile, Q10 connects those actions directly to the company’s wider system for ensuring quality^14,15.

3. Cleaning Validation Lifecycle:

Today’s way of checking cleanliness follows a step-by-step approach, much like how production processes are validated. Back in 2011, FDA guidance laid out a method split into three stages designing the process, testing it, then keeping an eye on it over time which quickly became standard practice across companies and oversight bodies. When it comes to cleaning checks, the idea stays the same build the cleaning method using data and hazard assessment, confirm it works via recorded tests, then keep it reliable with regular follow-ups and audits¹⁶.

3.1 Design Stage:

How things are set up gives a solid science foundation for the whole process. During this step, makers pick tools, items, and wash chemicals that show the toughest situations needing testing²⁵. Knowing how leftovers behave like if they dissolve easily, how strong or harmful they are, or if they react with other stuff matters a lot. Picking washing methods along with physical actions (say, water speed in automated systems or hand scrubbing smaller gear) needs backup from real tests or published studies. Good planning also uses risk checks (like FMEA or ranking risks), spotting spots where gunk might build up or spread between batches¹⁷. The design step clears up how to check if things are clean. Instead of just picking methods, it decides between swabbing or rinsing along with what exactly to test for. Limits on leftover stuff come from safety data, using numbers called MACO based on PDE info. Workers look at machine plans to find tricky spots like seals, spray nozzles, valves, or unused pipe ends. From this planning, tests are set up that spell out wash time, soap strength, heat levels, water amounts plus the pass-or-fail rules. This design step runs alongside gear checks (IQ/OQ) in auto cleaning setups so showing correct pump size, full spray reach, clean water supply, or accurate sensors matters. Getting the layout right early avoids most later issues^18,19.

3.2 Qualification Stage:

After designing and writing down a cleaning method, testing shows it actually works when used for real. Usually, three back-to-back cleanings happen per product type or toughest case. It passes only if tests confirm leftover amounts stay under the safe limit adjusted for how well the test itself detects stuff. They collect swab and rinse samples. once results repeat consistently, the method gets cleared for everyday use. Critical backup research in qualification involves. Recovery check: measures how much leftover stuff the method actually picks up. Checking test methods: makes sure they’re reliable, correct, clear, and sensitive enough when using health-based exposure limits. Cleaning residue checks make sure soap or neutralizer leftovers stay under safe levels. Microbiological check: makes sure microbes and toxins are under control, particularly in plants making biological medicines. Qualification reports need to cover sampling plans along with outcomes, any changes observed, plus final judgments each signed off officially by quality assurance. Once confirmed, cleaned settings like heat levels, mix strength, and duration range get added into either the main batch file or standard procedure guide^20,21.

3.3 Continued Verification Stage:

Once qualified, cleaning stays under control by checking it regularly this is step three. Instead of one-off tests, teams look at routine data like TOC or HPLC from changeover batches. Because trends show residue patterns over time, they spot slow changes before limits are missed²². Facilities often set regular check-ups every couple year or sooner if something big shifts, like a new product or machine update. When adjustments happen, they’re handled through official change tracking under the drug quality setup (ICH Q10). Lately, auditors see missing these follow-up checks as a serious cGMP issue²³. Digital tools for validation plus electronic records have updated how ongoing checks are done. Because of inline TOC, conductivity sensors, or fluorescence detectors tied into PAT systems, cleaning endpoints can now be spotted live. With these methods, test results come faster while also meeting data trust rules like ALCOA. Firms should regularly check if PAT readings still match older lab tests this keeps regulators on board²⁴.

4. Analytical Methods for Cleaning Validation:

Analytical testing is key in every cleaning validation effort. Even though paperwork and risk checks show purpose, lab analysis gives real data proving leftovers stay under set levels. Authorities want test methods to work reliably each one must spot traces far beneath the highest allowed carryover amounts based on safety studies, no matter the situation²⁵.

4.1 Sampling Strategies:

A solid analysis starts with good sample collection. Either swab or rinse methods are widely used around the world.

Swab Sampling:

Swab Sampling gives clear proof of how clean specific parts of equipment really are. Instead of dry tools, a damp neutral swab moves across a set area usually 25 cm² and later gets soaked in liquid for testing. This method checks high-risk spots like joints, seals, or edges, since leftovers often stay there.

Rinse Sampling:

Rinse Sampling checks inner parts of tricky machinery by looking at the last wash liquid. When wiping can't work like inside pipes or containers it offers a general overview. Using this alongside wipe tests brings full insight: one shows spot cleanliness, while the other proves broad effectiveness. No matter the method, authorities demand proof you can collect and measure a set portion of leftover material from a surface. Usually, grabbing at least 70 % works fine. Recording these pickup rates helps adjust lab numbers so they match actual levels on surfaces²⁶.

4.2 Common Analytical Techniques:

The method used relies on what the leftover stuff is like, how much there’s of it, also needs to match specific goals.

High‑Performance Liquid Chromatography (HPLC):

HPLC’s the go-to method when you need exact measurements of specific chemicals. It works well even at super low levels think parts per million or billion - and gives solid results for things like active drugs or leftover cleaning agents. Most times, reverse-phase setups paired with UV light or fluorescence detection do the job; but trickier compounds call for LC–MS/MS to pin down their structure.

Total Organic Carbon (TOC):

TOC testing checks how much organic stuff is in a sample but doesn't identify which compounds are present. It’s super quick, picks up tiny amounts, plus works well when checking mixtures where active ingredients look alike. Still, it can’t tell drug leftovers apart from other organics so you’ve got to back up its use with solid reasoning. Regulators are okay with TOC if tests show it can spot the compound way under MACO levels provided evidence backs it up. They’ll go along when proof confirms sensitivity far beneath the limit, though checks must support that claim. As long as results prove detection at much lower amounts than allowed, approval follows but only with solid data²⁷.

UV–Visible Spectroscopy:

Quick plus straight forward good for actives or cleaners that absorb UV light well. But since it’s less precise and needs more material to detect, you’d only use it if HPLC or TOC won’t work.

Microbiological Assays:

When gears used in clean or bio settings, check for germs and toxins too. Common checks are germ count (total plate method), LAL test (using horseshoe crab stuff) to spot endotoxins, also quick tests for living microbes. That way, cleaning steps actually reduce contamination risks²⁸.

4.3 Method Validation Requirements:

Methods used to check cleaning need proper testing under ICH Q2 rules along with GMP standards. Main factors to validate are. It measures just what it should, ignoring stuff like contaminants or wash chemicals. Sensitivity, LOD, or LOQ: can measure residue amounts at least ten times under the allowed limit. Accuracy plus precision shown via recovery tests and repeat checks. Linearity plus Range: solid link (R² ≥ 0.99) through the usual concentration stretches. Results stay reliable even if the method changes a little²⁹. Common validation rules follow ICH Q2 guidelines, shown in Table 1.

5. Risk‑Based Approaches to Cleaning Validation:

Risk-based thinking shapes how teams build, run, plus keep up cleaning checks these days. Efforts match real dangers to people or nature so work focuses on high-risk spots. This idea springs from ICH Q9 guidelines about handling quality risks, along with Q10 rules for drug quality systems. Cleaning proof isn't standalone it's part of an ongoing cycle tied to a facility’s broader safety net³⁰.

5.1 Principles of Quality Risk Management:

ICH Q9 defines risk management as “a systematic process for the assessment, control, communication, and review of risks to the quality of the drug product.” When it comes to cleaning checks, think about how likely leftover stuff like germs, chemicals, or tiny particles is to stick around; also consider how bad that could be for next batches or people using them; then look at whether we’d even notice if something went wrong. A solid grasp of recipe parts, production paths, or plant layout supports realistic risk assessment. The result Balanced oversight strong chemicals, toxic agents, or irritants need thorough decontamination plus separation; milder substances just call for basic proof of being clean^31.

5.2 Grouping and Bracketing Strategies:

Risk-based thinking helps sort products into groups to make testing easier. When items have alike recipes, how they clean up, or their toxicity level you can test them together, but only if real evidence shows they’re equal. For bracketing, pick the far ends of a product line like strongest and weakest dose, or what dissolves easiest and hardest; when both clear the bar, everything between is assumed fine. That cuts effort without losing oversight. Still, grouped setups need check-ups now and then toss in a new item that falls outside the current range, and it triggers fresh risk checks, maybe even extra tests³².

5.3 Risk Assessment Tools:

A variety of formal tools have been adopted to evaluate cleaning risk failure mode and effects analysis (FMEA) assign numerical ratings to severity (S), occurrence (O), and detectability (D). multiplying these yields a risk priority Number (RPN), and items with the highest RPN receive stronger control measures. Hazard analysis and critical control Points (HACCP) map the cleaning process, identifies points where contamination may occur, and establishes preventive monitoring parameters (e.g., rinse conductivity or TOC end points). Risk ranking and filtering (RRF) is especially useful for multiproduct facilities. Products are scored according to potency, toxicological data, solubility, ease of cleaning, and equipment contact area. This ranked list directs validation resources toward the most critical products. This method all rely on multidisciplinary input from production, toxicology, engineering, and QA. Risk assessments must living be living documents subject to periodic review as portfolios, processes, or active substances change³³.

6. Acceptance Criteria and Limits:

Acceptance criteria turn lab findings into clear cleanup goals. These guidelines spell out what "clean" actually looks like using numbers, setting hard limits on leftover traces after washing so gear stays safe for making medicine³⁴.

6.1 Traditional Acceptance Limits:

Over time, factories used easy yet not very scientific shortcuts to decide when things were clean enough. Common ones included. 10 parts per million (ppm) allowing up to 10 µg of the previous product per gram of the next, 0.001 of the smallest effective doses, so just 0.1 % of that daily minimum might remain, yet. Looks "neat" based on what the worker thought. Even though easy to figure out, these measures treated every active ingredient as if it worked the same way, no matter how strong or safe it was. As stronger medicines and fresh delivery methods came along, officials realized those set rules sometimes didn’t protect enough or went too far. Looking things over by eye still helps as a backup step if gear fails that basic look, it’s not clean. yet this kind of check doesn't replace actual lab testing^35,36.

6.2 Health‑Based Exposure Limits and Modern Approach:

Contemporary cleaning validation sets limits according to health‑based exposure limits (HBELs) expressed as permitted daily exposure (PDE) values. This approach links residue limits directly to toxicological data, ensuring consistency between cleaning control and patient safety science. EMA Annex 15 and PIC/S Annex 15 require manufacturers to adopt BBEL/PDE calculation or provide convincing scientific alternatives.

6.3 Health‑Based Exposure Limits and Modern Approach:

Nowadays, cleaning checks use health-based levels called PDE values to set safe limits. Instead of guesswork, these thresholds rely on toxicity info, tying cleanroom rules more closely to real patient risks. Guidelines from EMA Annex 15 along with PIC/S Annex 15 push companies to either apply HBEL/PDE math or back up any other method with solid proof. The PDE numbers get turned into surface limits using the MACO method from Section 5 so cleaning proof comes down to testing surfaces and showing leftovers stay under that MACO line. Since these thresholds depend on toxicity, they shift a lot between drugs, meaning validation teams must work hand-in-hand with lab techs and safety experts³⁷.

6.4 Comparison of Approaches:

The move from guesswork to science changed cleaning checks for good. Here’s how these two ways differ. The main differences between old-school, rule-driven cleaning checks and newer methods focused on health or risks are shown in Table 2.

7. Cleaning Validation in Different Manufacturing Scenarios:

Although the core principles of cleaning validation risk management, toxicology, and analytical verification are universal, their implementation must be tailored to the manufacturing environment. Equipment type, product characteristics, and production scale determine the degree of control and the techniques required³⁸.

7.1 Active Pharmaceutical Ingredient (API) Manufacturing:

API plants present unique challenges because residues can include potent intermediates, catalysts, and solvents. Synthetic steps may produce adherent or insoluble residues on reactor surfaces that resist conventional aqueous cleaning. Validation here focuses on removing reactive chemicals and verifying that cleaning agents do not alter equipment surface integrity.

Cleaning Approaches: aggressive acid or alkaline cleaning solutions, solvent flushes, followed by final purified water rinses. Analytical Testing: residual API levels by HPLC heavy metals by ICP MS, and TOC for non-specific organics. Risk focus: cross contamination between different chemical routes and interaction of residues with reactor materials. Documentation must confirm that residues are removed to levels below derived PDE limits and that equipment is chemically compatible with cleaning agents³⁹.

7.2 Biopharmaceuticals and Biologics:

Biopharmaceutical manufacture introduces bio‑derived contaminants such as proteins, nucleic acids, and microbial endotoxins. These materials can form biofilms on stainless steel surfaces are especially difficult to remove without denaturing agents or high temperature⁴⁰.

7.3 Single‑Use Systems and Automated CIP/SIP Systems:

Single use systems have transformed short run biotechnology and small batch operations by eliminating traditional cleaning requirements. Because bags, filters, and tubing are disposed after use, a forma cleaning validation is not required instead, validation shifts to extractables and leachable studies and confirmation of supplier integrity. For reusable equipment, automated CIP/SIP systems provide standardized cleaning cycles. Validation considers spray device coverage, flow velocity, detergent concentration, and rinse endpoint. PAT tools (YOC and conductivity sensors) allow real time verification of cleaning endpoint. These systems require periodic requalification to ensure spray pattern integrity and pump performance^41.

8. Challenges And Common Pitfalls:

Even with the presence of strong regulations and defined methodologies for cleaning validation, this scientific discipline remains one of the most frequent sources of GMP inspection findings. Many failures arise not from a lack of technology but through incomplete implementation, weak documentation, or inadequate scientific justification. Understanding these common pitfalls will enable organizations to proactively reinforce programs to deter compliance risks⁴².

8.1 Risk of Cross‑Contamination:

The principal risk of any pharmaceutical process is the unintended carryover of residues from one batch or product into another. Contamination can result from poorly designed equipment, flawed gaskets, incorrect labelling of lines, or insufficient segregation of operators and air flows. Control measures include validated cleaning in place (CIP) system with verified spray coverage, risk-based equipment segregation, and humidity or air pressure differentials between processing areas. For highly potent APIs, containment and dedicated equipment is required⁴³.

8.2 Sampling and Analytical Errors:

Analytical accuracy hinges on proper sampling, which is where the most common failures occur. Common pitfalls include poor definition of the location to be sampled, not conducting recovery validation for each surface type, and operator-dependent swabbing pressure and direction. Swab materials not validated may either absorb or repel residues, reporting false results. Analytical mistakes such as using methods above their limit of quantitation for PDE based values will also lead to wrong conclusions. Regular training, inter-analyst comparisons, and re-validation of methods are paramount to having assurance of the data⁴⁴.

8.3 Documentation and Data Integrity:

Regulators cite documentation issues in almost every inspection. Missing signatures, uncontrolled spreadsheets, and inconsistent record keeping undermine otherwise sound programs. Agencies apply the ALCOA principles (Attributable, Legible, Contemporaneous, Original, Accurate to all validation data⁴⁵.

8.4 Summary of Common Pitfalls and Solutions

Common issues noted during inspections, along with the prevailing prevention measure Pursued by industry, are given in table 3.

9. Emerging Trends and Technologies:

The last decade has seen major technological and conceptual advances in cleaning validation driven by data‑integrity initiatives, digital transformation, and the rise of continuous manufacturing. Modern tools now allow residues to be monitored and verified in real time, shorten turnaround times, and enhance confidence in data reliability⁴⁶.

9.1 Real‑Time Monitoring and Process Analytical Technology (PAT):

Traditional cleaning validation used off‑line analysis of swab or rinse samples, which is time‑consuming and extends equipment downtime. Process Analytical Technology (PAT) is changing this model by embedding sensors and analytics directly into the cleaning system. Common technologies include: In‑line Total Organic Carbon (TOC) sensors, that measure organic residues in final‑rinse water, release equipment only when readings fall below pre‑set thresholds. conductivity and pH sensors, which confirm the removal of detergent and neutralization of cleaning agents. Optical and fluorescence detectors, which detect trace proteins or surfactants in biopharmaceutical systems. Spectroscopic methods (NIR, Raman), which can carry out instantaneous surface scans of equipment without any need for sampling. these instruments, when integrated with programmable logic controllers (PLCs), provide end‑point determination that is, the system automatically ends a cycle when sensor data confirm compliance. Real‑time data also create permanent electronic records in compliance with ALCOA and data‑integrity principles.

9.2 Continuous Manufacturing and Advanced Cleaning Concepts:

As pharma moves to continuous manufacturing, cleaning validation is shifting to long-running systems where it is impractical to stop production for full manual cleaning⁴⁸. New strategies include in‑situ flushes while equipment remains operational, “campaigning” of compatible products, and short cleaning by design steps integrated into the process flow. validation then focuses on defining steady state cleanliness and pre-establishing residue limits for transition points Mathematical models simulate residue decay and predict rinse volumes needed to reach MACO targets. Regulators encourage these innovations providing companies can demonstrate equivalent assurance of control. EMA and FDA identify continuous manufacturing validation as a key topic for future guidance development⁴⁹.

9.3 Automation and Data Integrity:

Automation does not stop with mechanical cleaning aids. Validation planning, execution, and reporting are managed, to a growing extent, via electronic validation lifecycle management systems. These systems house templates, record instrument results, manage review loops, and produce audit-ready reports. Benefits include: Uniform document formats, automatic revision control^50.

9.4 Digital Transformation and Global Harmonization:

Digitalization is pushing industry toward paperless cleaning validation lifecycle models with instant traceability from design to revalidation. Regulatory authorities (FDA, EMA, PLC/S) endorse this trend because it strengthens data integrity and reduces huma error. On a global scale, initiatives such as the WHO-ICMRA convergence project are fostering uniform adoption of HBLC and digital standards for validation data exchange. Parallel to digital progress is a growing emphasis on sustainability. Environmentally friendly detergents, recycling rinse water, and energy efficient CIP systems demonstrate that process safety and ecological responsibility can coexist. AI-driven cycle optimization is likely to further reduce carbon and resource footprints⁵¹.

10. Case Studies and Industry Best Practices:

Case studies of real‑world applications show how theoretical cleaning‑validation principles are transformed into practical compliant programs. The mistakes that frequently occur and some lessons that regulators wish manufacturers would learn are also demonstrated. The following examples, derived from published literature, together with anonymized regulatory feedback, demonstrate success and failure scenarios⁵².

10.1 Lifecycle Cleaning Program Implementation:

A large multiproduct solid dosage plant undertook a complete overhaul of its legacy cleaning program. Previously, the relied on a generic 10 ppm criterion and visual inspection alone. In response to updated European and PIC/S guidance, the company re-established acceptance criteria using HBEL/PDE values for each API and classified equipment by risk level. Representative products (short half-life, highest toxicity, lowest solubility) were validated as worst cases; all other were covered by bracketing logic. the results indicated higher efficiency and fewer deviations. The entire data of the validation lifecycle was managed electronically by a digital validation management system, ensuring reviewable audit trails. During the inspection by EMA, no major findings were observed at this site, which was also recognized for its scientific transparency and integrity in data.

10.2 Failed Sampling and Regulatory Observation:

A sterile injectables contract manufacturer received an FDA warning letter for lack of validatedsampling methods and inadequate re‑validation after product changes. The facility used only rinse samples from complex filling lines; swabs were not feasible and no rationale was documented. Residues of a preservative contaminated subsequent batch, triggering product recall. FDA required a comprehensive plan to validate both sampling techniques and analyticalmethods with recovery studies on every surface type. Lesson learned: each sampling approach must be risk-based and scientifically defended. An appropriate statistical rationale in respect of number and location of samples, as required by Annex 15, would therefore avoid such situations in the future.

10.3 Collaborative Data‑Sharing and Toxicology Support:

Smaller companies frequently do not employ in‑house toxicologists to calculate HBEL/PDE values. A network of contract manufacturers and consulting experts formed the Global HBEL Alliance, creating a shared database of toxicological evaluations and PDE values for commonly handled actives. This cooperation was consistent and ensured regulatory acceptance while minimizing duplication of effort. Such co-operative initiatives are increasingly encouraged by industry associations (ISPE, PDA) in order to achieve global harmonization⁵¹.

10.4 Consolidated Best Practices:

Drawing from industry case studies, regulatory observations, and professional guidance documents, certain best practical themes emerge. Risk proportionality. Validation scop should match product potency and equipment risk. HBEL/PDE Adoption: All the residue limits should be toxicology driven and reviewed periodically with expert approval. Validated Sampling and Analytical Methods: SWAB and rinse procedures must have demonstrated recoveries and sensitivity to 10 % of MACO. Automation and Data Integrity: Electronic records and real-time monitoring enhance transparency and minimize human error. Lifecycle Management: Validation does not end with initial approval. periodic reviews and trend analysis are essential. Training and Quality Culture: Empowerment of operators and analysts on the understanding of risk and scientific rationale is paramount. These principles are now reflected in most regulatory audit checklists and professional training syllabi. Firms that implement them experience fewer non-conformities and lower operational costs while enhancing patient protection⁵¹.

10.5 Collaborative Data‑Sharing and Toxicology Support:

Smaller companies often lack in house toxicologists to calculate HBEL/PDE values. A network of contract manufacturers and consulting experts formed the Global HBEL Alliance, creating a shared database of toxicological evaluation and PDE values for commonly handled active. The is collaboration ensured consistency and regulatory acceptance while reducing Duplication of effort. Such cooperative initiatives are increasing encourages by industry associations (ISPE, PDA) to achieve global harmonization⁵².

11. CONCLUSION:

Cleaning validation has matured from a narrow compliance exercise into a comprehensive scientific discipline, integrating toxicology, analytical chemistry, risk management, and digital data integrity. Its aim stays the same: to show that pharmaceutical equipment is clean enough to protect patients from unintentional exposure. Yet the methods and expectations surrounding that objective keep evolving at a remarkable pace.

12. REFERENCES:

1. US Food and Drug Administration (FDA). Guide to Inspections of Validation of Cleaning Processes. Rockville (MD): FDA; 1993.

2. European Commission. EudraLex Volume 4 Annex: Qualification and Validation. Brussels: European Commission; 2015.

3. Walsh A, O Donnell K. Cleaning validation: current perspectives. PDA J Pharm Sci Technol. 2012; 66(5).

4. Bachhav R, Bachhav P, Bhamare M, Bachhav R, Sonawane G, Pansare K, Patil D. Review of high-performance liquid chromatography and its applications. J Pharm Pharm Sci. 2023; 12(3): 1-15.

5. International Society for Pharmaceutical Engineering (ISPE). ISPE Good Practice Guide: Cleaning Validation Lifecycle Applications, Methods, and Controls. Bethesda (MD): ISPE; 2018.

6. Kommanaboyina B, Basha C, Varshitha J, Sai Kiran G. Cleaning validation: current trends. J Pharm Sci Res. 2016; 8(8): 793‑802.

7. Harding WM. Cleaning validation in the pharmaceutical industry. J Parenter Sci Technol. 1992; 46(1): 4‑11.

8. US FDA. Guidance for Industry: Process validation General Principles and Practices. Silver Spring (MD): FDA; 2011.

9. International Council for Harmonization (ICH). Q9: Quality Risk Management. Geneva (CH): ICH; 2005

10. European Medicines Agency (EMA). Questions and Answers on Health based Exposure Limits (HBELs) and Cleaning Validation. Amsterdam (NL): EMA; 2018

11. Pharmaceutical Inspection Co-operation Scheme (PIC/S). Guide to GMP for Medicinal Products Annex 15: Qualification and Validation. Geneva (CH): PIC/S; 2021.

12. World Health Organization (WHO). WHO Technical Report Series No. 986 Annex 2 Good Manufacturing Practices for Pharmaceutical Products. Geneva (CH): WHO; 2014.

13. Word Health Organization. WHO Technical report Series No. 937 Annex 3: Guidelines on Validation. Geneva (CH): WHO; 2006.

14. Sandle T. Cleaning validation potent molecules. Eur Pharm Rev. 2017; 22(4): 44‑48.

15. Rathore AS. Controlling carry‑over in potent molecule manufacturing. Biopharm Int. 2015 Jul; 28(7): 40‑46.

16. Gough JD. Risk‑based cleaning validation. J Validation Technol. 2018 Summer; 24(3): 29‑37.

17. United states Food and Drug Administration. 21 CFR Part 211 current GMP Practical for Finished Pharmaceuticals. Washington (DC): US Government Printing Office; 2022.

18. Oldfield R, Barrow G. Microbial aspects of cleaning validation. PDA J Pharm Sci Technol. 2015; 69(2): 240‑252.

19. Fourman GL, Mullen MV. Determining cleaning validation acceptance limits for pharmaceutical operation. Pharm Technol. 1993 Apr; 17(4): 54-60.

20. Fricke R, Hein EM. Regulatory aspects of cleaning validation in multipurpose facilities. PDA J Pharm Sci Technol. 2016 Nov-Dec; 70(6): 530-538.

21. US FDA. Warning Letter: Bausch & Lomb Incorporated Cleaning Validation Deficiencies. Silver Spring (MD): FDA; 2017.

22. European Medicines Agency (EMA). Compilation of Community Inspection Findings on Cross‑Contamination and Cleaning Validation. Document No. EMA/INS/GMP/798546/2011. Amsterdam (NL): EMA; 2018.

23. Madsen RE, Schmidt T, Keller M. Validation of swab recovery in pharmaceutical cleaning processes. J Validation Technol. 2015 Spring; 21(2): 35‑42.

24. Shirodkar S, Kulkarni A, Rathi S, Patil S Design considerations in cleaning validation: API properties and cleaning agent selection. J Pharm Sci Tech. 2017 May‑Jun; 71(3): 210‑218.

25. Hussain A, Khan H, Patel D, Singh R. Cleaning agents and their control in pharmaceutical manufacturing. Pharm Eng. 2016 Jul‑Aug; 36(4): 45‑52.

26. Jenke D. Equipment material and design impacts on cleaning validation. PDA J Pharm Sci Technol. 2015 Nov‑Dec; 69(6): 709‑720.

27. Bachhav R, Bachhav P, Bhamare M, Bachhav R, Sonawane G. A concise review on high-performance liquid chromatography. J Pharmaceut Res. 2023;8(2):340-51.

28. Huber L. Application of total organic carbon analysis in cleaning validation. Eur J Pharm

29. Sci. 2019; 133: 105‑112.

30. Sherma J, Fried B. Handbook of Thin-Layer Chromatography and UV Analysis. Boca Raton (FL): CRC press; 2017.

31. International Council for Harmonization (ICH). Q2(R1): Validation of Analytical Procedures Text and Methodology. Geneva (CH): ICH; 2005.

32. Hawk B, Christensen D, Lewis T. Advanced LCMS applications for cleaning validation of highly potent molecules. J Pharm Innov. 2017; 12(4): 325‑334.

33. Li Z, Chen Y, Wang K. Process Analytical Technologies (PAT) for cleaning validation. Anal Chem Rev. 2020; 92(12): 7896‑7910.

34. EMA/CHMP/CVMP/SWP/169430/2012 Rev 1. Guideline on Setting Health-Based Exposure Limits for Use in Risk Identification in Shared Facilities. EMA; 2014.

35. O’Donnell K, Walsh A. Applying quality risk management to cleaning validation programsJ Validation Technol. 2016; 22(3): 16‑27.

36. Singh SP, Mehta S, Patel V. Implementation of FMEA in cleaning validation risk assessment. Pharm Eng. 2018; 38(2): 40‑53.

37. Pizzorno F, Alvarez R. Application of HACCP principles in cleaning validation of biotech facilities. Bioprocess j. 2017; 16(4):30-38.

38. Pezzini A, Carlton R, Hall E. Risk ranking and filtering strategies for multiproduct cleaning validation. PDA J Pharm Sci Technol. 2019; 73(5): 467‑476.

39. ISPE. Good Practice Guide: Health‑Based Exposure Limits. North Bethesda (MD): ISPE; 2016.

40. Thiel W, Klinkenberg M. Scientific justification of grouping and bracketing approaches in cleaning validation. J Pharm Innov. 2020; 15(2): 145‑158.

41. PIC/S. Aide‑Memoire on Cleaning Validation. PIC/S PI 006‑3; 2021.

42. Angell R. Historical evolution of cleaning validation limits. Pharm Technol. 2014; 38(9): 34‑41.

43. McCormack K, Motupalli S. Limitations of the 10ppm concept in cross contamination control. J Validation technol. 2015; 21(3): 60-70.

44. Sandle T. Visual inspection thresholds and human factors in assessing cleanliness. Eur pharm Rev. 2018; 23(2): 52-57

45. Byrn SR, Mercer E. Establishing safety margins in PDE based cleaning limit. PDA J Pharm Sci Technol. 2019; 73(1):12-26.

46. Wilkins C, Reddy P. Residue characteristics in API manufacturing and implications for cleaning. Org Process Res Dev. 2016; 20(8): 1341-1349.

47. Chakraborty S, Das R. Solvent selection and environmental aspects of chemical cleaning in multipurpose API plants. J Cleaner Prod. 2017; 165: 1373‑1382.

48. Luo J, Greenspan S. Use of ICP-MS for heavy metal residue analysis in reactor cleaning validation. J Pharm Sci Tech. 2019; 73(4): 412-420.

49. WHO. Tech Report Series No. 999 Annex 2 Cleaning Validation in Biological Manufacturing. Geneva (CH): WHO; 2018

50. Bodendorf C, Schneider U. Enzymatic cleaning agents for removal of proteinaceous residues. Biotechnol Progress. 2018; 24(6): 1348-1356.

51. Rosen J, Paterson A, Miller C. Analytical methods of residual DNA and protein in biologics cleaning validation. PDA J Pharm Sci Technol. 2019; 73(2): 140-150

52. Jenke D. Extractables and leachable considerations for single use systems. Pharma Eng. 2020; 40(5): 32-45

53. Garcia M, Linton K. LC-MS/MS determination of cytotoxic drug residues in HPAPI facilities. J Pharm Innov. 2021; 16(3): 310‑322.

Received on 28.04.2026 Revised on 16.05.2026

Accepted on 03.06.2026 Published on 04.07.2026

Available online from July 30, 2026

Asian J. Research Chem.2026; 19(4):326-334.

DOI: 10.52711/0974-4150.2026.00051

This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License.

Parameter	Purpose	Acceptance Criterion
Specificity	Differentiates target residue from matrix	No interference detected
Recovery	Determines sampling efficiency	≥ 70 %
LOD/LOQ	Lowest detectable or quantifiable limit	≤ 10 % of MACO value
Linearity	Confirms proportional response	Correlation coefficient R² ≥ 0.99
Precision	Repeatability of measurements	%RSD ≤ 5 %
Robustness	Assesses method stability to minor changes	No significant difference

Aspect	Traditional Approach	Modern Health‑Based / Risk Approach
Acceptance limits	Fixed 10 ppm or 0.001 Dose rule	HBEL / PDE toxicology‑derived limits
Scientific basis	Empirical, not compound‑ specific	Toxicological data, pharmacological assessments
Anaytical methods	Visual or UV testing	HPLC, TOC, LC–MS/MS validated methods
Validation scope	Equal focus for all product	Risk ranking and bracketing strategies
Lifecycle management	One‑time qualification	Continuous monitoring and verification

Common Challenge	Best Practice / Preventive Measure
Cross contamination risk	Validate CIP coverage; segregate equipment; enforce containment for potent products.
Inadequate sampling	Perform validated recovery studies for each surface type; standardize technique and training.
Analytical insensitivity	Use HPLC or LCMS to achieve LOD ≤ 10 % of MACO; periodically re‑validate methods.
Poor documentation	Adopt electronic systems with audit trails; apply ALCOA principles to all records.
Inconsistent limits	Base all limits on PDE/HBEL calculations; maintain central registry with QA/Toxicology approval.
Re‑validation gaps	Define change‑control triggers (new product, equipment changes); schedule periodic review every 2–3 years.